OptimizeRx’s (OPRX) “Sell (D-)” Rating Reiterated at Weiss Ratings

OptimizeRx (NASDAQ:OPRX)‘s stock had its “sell (d-)” rating restated by stock analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Several other research firms have also commented on OPRX. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Citigroup reissued an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. JMP Securities increased their target price on OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, October 10th. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a report on Friday, August 8th. Finally, UBS Group set a $23.00 target price on OptimizeRx in a report on Friday, October 10th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus price target of $13.39.

OptimizeRx Stock Performance

NASDAQ:OPRX opened at $21.68 on Friday. The firm has a market capitalization of $402.60 million, a PE ratio of -40.15 and a beta of 1.25. The business’s fifty day moving average price is $18.39 and its 200 day moving average price is $14.33. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $21.99.

Insider Activity

In other OptimizeRx news, Director Patrick D. Spangler sold 11,120 shares of the firm’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $17.49, for a total transaction of $194,488.80. Following the transaction, the director owned 44,215 shares of the company’s stock, valued at approximately $773,320.35. This trade represents a 20.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the transaction, the chief executive officer directly owned 188,916 shares in the company, valued at approximately $3,542,175. The trade was a 0.85% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently made changes to their positions in OPRX. Nisa Investment Advisors LLC boosted its stake in shares of OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after buying an additional 1,818 shares during the period. Quantbot Technologies LP acquired a new stake in shares of OptimizeRx during the second quarter worth about $44,000. BNP Paribas Financial Markets boosted its stake in shares of OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of OptimizeRx during the first quarter worth about $99,000. Finally, Virtu Financial LLC acquired a new stake in shares of OptimizeRx during the first quarter worth about $112,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.